And so we don't know. And certainly cannot "follow the science" to policy conclusions.
Show this thread
Not a randomized trial. Thus we cannot know how the 3rd dose group differed in variable demographic a priori health features that can only be controlled by randomization. A fatal flaw.https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02249-2/fulltext …
-
-
-
And we can't merely say "this is the best we can do under the circumstances " as scientists when our conclusions are used to drive policy. What's worse than ignorance? Premature and unreliable conclusions wearing the mantle of scientific fact.
Show this thread
End of conversation
New conversation -
-
-
They don't care.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Another flaw is that the maximum follow up period for dose 3 has to be less than 3 months based on the dates. It seems clear that the boosters provide a substantial immunity bump but the important question is "for how long?"
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
It’s a matched case-control study. It’s wrong to say that *only* randomisation can control for these factors. And it’s a “limitation” not a fatal flaw. You know full well that science isn’t this black-and-white.
-
I think it’s satire on the ivermectin front. Although there were meta analysis out supporting it’s use, a bunch of people said it can’t be trusted due to no RCT being done
End of conversation
New conversation -
-
-
It was not a trial either, but an evaluation of existing data. Right now we just don't have anything better. There is no enough time for a randomized study.
-
and so we move forward risking peoples health to find out.
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.